COMP <GO>
BSX vs JNJ // 10Y YIELD & FRED MACRO BETA
Boston Scientific Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BSX 6
— JNJ 7
▲ 10Y YIELD & FRED MACRO BETA LEADER: JNJ
LAST: $41.98 (-1.66%) • MKT CAP: $61.87B
macro-sensitivity
0.99
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BSX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BSX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.00% | 67.90% | +1.10 | BSX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.20% | 25.50% | -16.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.8x | 18.5x | -2.70 | BSX | /valuation <GO> |
| Free Cash Flow Yield | 5.91% | 2.97% | +2.94 | BSX | /fcf-yield <GO> |
| Operating Margin | 18.00% | 34.70% | -16.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 14.00% | 28.50% | -14.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 19.90% | 6.00% | +13.90 | BSX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.77 | 5.59 | -2.82 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | BSX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.8 | 60.4 | -21.58 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.99 | 1.08 | -0.09 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.5x | 23.0x | -4.50 | BSX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $61.87B | $662.49B | -$600.62B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BSX REV | JNJ REV | BSX GROSS % | JNJ GROSS % | BSX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.07B | $94.19B | 69.0% | 67.9% | $3.66B | $19.70B |
| FY 2024 | $16.75B | $88.82B | 68.6% | 69.1% | $2.65B | $19.84B |
| FY 2023 | $14.24B | $85.16B | 44.0% | 44.0% | $1.86B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BSX // BETA 0.99
JNJ // BETA 1.08